NCT01497431View on ClinicalTrials.gov

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
No Evidence of DiseaseProstate Carcinoma
Interventions
DIETARY_SUPPLEMENT

Selenium

Given PO

OTHER

Placebo

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Methylselenocysteine

Given PO

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

37232

Vanderbilt-Ingram Cancer Center, Nashville

60611

Northwestern University, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01497431 - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants | Biotech Hunter | Biotech Hunter